Abliva resolves on directed issue of convertibles amounting to SEK 26 million
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER REGARDING ANY SECURITIES IN ABLIVA.
The Board of Directors of Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”) has today resolved to issue convertibles corresponding to SEK 26 million, subject to the approval of an extraordinary general meeting, directed to the Company’s largest shareholder Hadean Ventures through its two funds Hadean Capital I AS and HVentures Capital I AB (the “Convertible Issue”). Hadean Ventures is an Oslo Stockholm-based investor who currently owns 14.9 percent of the outstanding shares in Abliva. The Board of Directors will summon to an extraordinary general meeting (“EGM”) for approval of the Board of Directors’ resolution on the Convertible Issue. The notice for the EGM, planned to be held on January 14, 2022, will be announced through a separate press release.
Summary of the Convertible Issue
- The Convertible Issue consists of 260 convertibles at a nominal value of SEK 100,000 per convertible (the “Convertibles”). The subscription price shall be equal to the nominal value of the Convertibles with a deduction of a set-up fee of 3.95 percent.
- The Convertibles carries an annual interest rate of 10 percent of their nominal value.
- The term of the Convertibles is 12 months with a maturity date on December 20, 2022, to the extent conversion has not taken place before such date.
- The conversion price will either be (i) same price as other investors in a potential capital raise conducted before 2022-05-22, or (ii) 10-day VWAP prior to conversion request date.
With a conversion price based on 10-day VWAP and at full conversion of the Convertibles, calculated as of the date of this announcement, the dilution would amount to approximately 10.7 percent, meaning that the Company’s share capital would increase by SEK 2,418,739.55, and the number of shares in the Company would increase by 48,374,791 shares.
The terms and conditions for the convertible loan, including the conversion price, have been established after arms’ length negotiations with Hadean Ventures and following the recommendation from an independent investment bank. Thus, the Board of Directors’ assessment is that the terms and conditions of the Convertibles are in accordance with market conditions.
The Company intends to use the net proceeds from the Convertible Issue for further advancement of KL1333 and provide bridge financing as the Company continues discussions with investors and potential strategic partners. The reasons for the deviation from the shareholders’ preferential rights is to be able to carry out a capital raise in a timely and cost-effective manner from the major shareholders. The Board of Directors believes that it is advantageous for the Company and for the Company's owners to capitalize on the flexibility to raise capital on favourable terms and in a timely and cost-effective manner from the major shareholders. The Board of Directors therefore believes that the Convertible Issue will promote value creation for all shareholders of the Company.
Advisors
Erik Penser Bank AB is financial advisor and Cirio Advokatbyrå AB is legal advisor to Abliva in connection with the Convertible Issue.